February 23, 2023— Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022.
Moderna(NASDAQ:MRNA) reported Q4 earnings of $3.61 per diluted share, Analysts polled by Capital IQ expected $4.75.
Moderna(NASDAQ:MRNA) Revenue for the quarter ended Dec. 31 was $4.86 billion, Analysts surveyed by Capital IQ expected $5.02 billion.
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61。
Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12。
Cash used for repurchases of common stock was $3.3 billion for the full year 2022.
Business outlook:
The Company expects product sales in the first half of 2023 of approximately $2.0 billion.
Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses: Full-year expenses are expected to be approximately $6.0 billion, with approximately $4.5 billion in R&D.
Capital Expenditures: The Company expects capital investments for 2023 of approximately $1.0 billion.
The $3 billion share repurchase program announced in February 2022 was completed early in the fourth quarter 2022. The Company has commenced repurchases from the additional $3 billion program announced in August 2022, and currently has $2.8 billion remaining under this latest authorization.
Moderna had approximately 3,900 employees as of December 31, 2022, compared to approximately 2,700 employees as of December 31, 2021.
MODERNA, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME